Drug Trial Radar · NCT04791579
Antibiotic Prophylaxis for Neurogenic Bladder Botox
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Mar 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- University of AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Injection of Botox into the bladder is a procedure used to treat neurogenic overactive bladder at the Dianne and Irving Kipnes Urology Centre in the Kaye Edmonton Clinic. A common complication following bladder Botox is bladder infection. There are no well-studied preventative antibiotics given at the time of bladder Botox for the reduction of post-operative bladder infection. We are proposing a research study that will randomize participants into two groups - one receiving antibiotics and the other receiving placebo pills following bladder Botox. The main goal of our study is to determine if preventative antibiotics at the time of bladder Botox injection reduces post-operative bladder infection. It will provide a valuable learning opportunity for a trainee starting their academic career through working closely with established researchers across two disciplines. We hope the results of our study can ultimately be used to improve outcomes and safety for a common Urologic procedure. In addition, findings from our study could help reduce unnecessary use of antibiotics resulting in cost savings in the health care system and reduction in the risk of antibiotic resistance.
Conditions
- Neurogenic Bladder
- Post-operative Urinary Tract Infections
Interventions
CiprofloxacinDrug
Fluoroquinolone antibiotic
PlaceboDrug
Placebo pill
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Postoperative Urinary Tract InfectionTime frame: 2 weeks following the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alberta
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.